NCT05662592

Brief Summary

Evaluation of Broadband Light Treatment Protocols for Pigmented Skin Lesions - A comparative study

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 6, 2022

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 22, 2022

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2023

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 6, 2023

Completed
Last Updated

December 1, 2023

Status Verified

November 1, 2023

Enrollment Period

8 months

First QC Date

December 6, 2022

Last Update Submit

November 29, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in pigmentation, skin tone and texture

    Change in pigmentation, skin tone and texture will be evaluated using photographs captured at baseline and 4-6 weeks post treatment

    4-6 weeks

Study Arms (1)

Treatment Arm

EXPERIMENTAL

Broadband light treatment will be provided on pigmented skin lesions

Device: Broadband Light

Interventions

Broadband Light device will be used for treatment of pigmented skin lesions

Treatment Arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy male or female, 18 years or older
  • Fitzpatrick skin type I-IV
  • Has visible signs of moderate to severe skin pigmentation
  • Willing to not use any other procedure(s) in the treatment area during the study, such as laser- or light-based treatment, non-light-based device treatment such as radiofrequency or ultrasound, injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler, chemical peel, or surgical procedure
  • Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant for the duration of the study. (applicable to female subjects only)
  • Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treatment area every day for the duration of the study, including the follow-up period
  • Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes
  • Subject must agree to not make any changes in their skin regimen for the duration of the study, including the follow-up period
  • Subject must be able to read, understand and sign Informed Consent Form
  • Must be willing to adhere to the treatment and follow-up schedule and post-treatment care instructions

You may not qualify if:

  • Fitzpatrick skin type V-VI
  • Participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study.
  • Any type of prior cosmetic treatment to the target area within 3 months of study participation, such as laser or light-based procedures or surgery.
  • Prior injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler in the target area within 1 week of study participation.
  • History of malignant tumors in the target area.
  • Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles.
  • Pregnant and/or breastfeeding (applicable to female subjects only)
  • Having an infection, dermatitis or a rash in the treatment area.
  • Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.
  • Suffering from coagulation disorders or taking prescription anticoagulation medications.
  • History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
  • History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
  • History of vitiligo, eczema, or psoriasis.
  • History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
  • History of seizure disorders due to light.
  • +10 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

New Jersey Plastic Surgery

Montclair, New Jersey, 07042, United States

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 6, 2022

First Posted

December 22, 2022

Study Start

October 1, 2022

Primary Completion

May 30, 2023

Study Completion

June 6, 2023

Last Updated

December 1, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations